CurrentCignaPolicy IP0468

Ciprofloxacin/fluocinolone (Otovel) otic solution coverage

Defines medical necessity and coverage criteria for ciprofloxacin/fluocinolone otic solution (Otovel) for treatment of acute otitis media with tympanostomy tubes in eligible members of Cigna-administered health plans.

Policy Summary

PayerCigna

PolicyCiprofloxacin/fluocinolone (Otovel) otic solution coverage

Policy CodePolicy IP0468

Change TypeNo material changes

Effective DateJan 1, 2023

Next Review DateJan 1, 2024

Key ActionObtain prior authorization and document age, AOMT diagnosis, and trial/failure or intolerance to preferred alternatives (or preservative hypersensitivity) when requesting coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 months–<18 yrsage range specified for coverage

AOMTindication covered

up to 12 monthsinitial approval duration

preferred trialstep therapy requirement

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Any use of ciprofloxacin/fluocinolone otic solution (Otovel) that does not meet the policy’s specified coverage criteria for acute otitis media with tympanostomy tubes is considered experimental, investigational or unproven and is not covered.

Initial Therapy Criteria

Reauthorization / Continuation Criteria

Reauthorization

Reauthorization and continuation rules

Reauthorization beyond the initial approval duration is not applicableInitial approval up to 12 months

Initial approval duration: up to 12 months; reauthorization approval duration: not applicable

Provider Actions and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for the bioequivalent generic product (ciprofloxacin-fluocinolone 0.3%/0.025% otic solution).

Prior authorization required for ciprofloxacin-fluocinolone 0.3%/0.025% (bioequivalent generic of Otovel).

Step Therapy

Step Therapy Required

Step therapy: A trial of the preferred product is required prior to coverage of the non-covered product unless there is inadequate response or intolerance.

Preferred product required: ciprofloxacin 0.3% + dexamethasone 0.1% otic suspension.
Coverage of ciprofloxacin-fluocinolone (Otovel or bioequivalent) allowed only after inadequate response or intolerance to the preferred product or when preservative hypersensitivity exists.

Documentation Required

Documentation Requirements

Documentation required: Document patient age, diagnosis, and trial/failure or intolerance to the preferred alternative (or documented preservative hypersensitivity).

Document patient age: 6 months to <18 years.
Document diagnosis: Acute Otitis Media with Tympanostomy Tubes (AOMT).
Document evidence of trial and inadequate response or intolerance to ciprofloxacin 0.3% + dexamethasone 0.1% otic suspension, or documentation of known hypersensitivity to a preservative (e.g., benzalkonium chloride, benzyl alcohol).
If seeking ciprofloxacin-fluocinolone (bioequivalent generic), document why the bioequivalent formulation cannot be used due to inactive-ingredient-related allergy or serious adverse reaction.

Denial Risk

Denial Risk and Conditions

Denial risk: Coverage may be denied if used for indications other than AOMT, if age criteria are not met, or if criteria for alternatives/intolerance are not satisfied.

Coverage may be denied for any use other than Acute Otitis Media with Tympanostomy Tubes (AOMT).
Coverage may be denied if patient is outside the age range (6 months to <18 years).
Coverage may be denied if there is no documented trial and inadequate response or intolerance to the preferred product (ciprofloxacin 0.3% + dexamethasone 0.1%) and no documented preservative hypersensitivity.
Use of ciprofloxacin-fluocinolone without prior authorization where required may result in denial.

Step Therapy Requirements

Step	Requirement
1	Trial of the preferred otic product (ciprofloxacin 0.3% + dexamethasone 0.1% otic suspension) is required unless there is documentation of intolerance, inadequate response, or known preservative hypersensitivity (e.g., benzalkonium chloride, benzyl alcohol).

Site of Care

Note

Site of care — reasonable and clinically appropriate

Site of care should be reasonable and clinically appropriate for the member; no specific site restrictions are specified in the policy.

Definitions

AOMT definition

TermAcute otitis media with tympanostomy tubes (AOMT)

DefinitionAcute infection/otorrhea occurring in patients with tympanostomy tubes

Typical pathogensStaphylococcus aureus; Streptococcus pneumoniae; Haemophilus influenzae; Moraxella catarrhalis; Pseudomonas aeruginosa

Age scopePediatric patients aged 6 months and older

Recommended local therapyOtotopical antibiotics are recommended (per AAO-HNSF) for uncomplicated acute tympanostomy tube otorrhea

Background

Ciprofloxacin/fluocinolone otic solution is a combination antibacterial and corticosteroid formulation indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients aged 6 months and older. Ototopical antibiotic-corticosteroid preparations are used to achieve high local drug concentrations at the site of tympanostomy tube otorrhea while minimizing systemic exposure.